

## CONTENTS

1. General Immunology of Lymph Node and Spleen . . . . .	1
Overview of the Immune System and Immunologic Responses. . . . .	1
Lymph Nodes . . . . .	1
Anatomy . . . . .	1
Primary Immune Response . . . . .	1
B Lymphocytes. . . . .	3
T Lymphocytes. . . . .	8
Natural Killer Cells. . . . .	9
Dendritic Cells . . . . .	10
Spleen . . . . .	11
Anatomy . . . . .	11
White Pulp . . . . .	11
Marginal Zone . . . . .	13
Red Pulp . . . . .	14
2. Embryology and Histology of the Lymph Node and Spleen. . . . .	19
Embryology of the Spleen . . . . .	19
Embryologic Abnormalities of the Spleen . . . . .	19
Accessory Spleen, Ectopic Spleen, and Polysplenia. . . . .	19
Wandering Spleen . . . . .	22
Abnormal Fusion: Splenogonadal, Splenorenal, Hepatolienal Fusion . . . . .	23
Asplenia . . . . .	24
Embryology of the Lymph Nodes . . . . .	24
Ectopia in Lymph Nodes . . . . .	25
Histology of Lymph Node (Normal Architecture and Function of Lymph Nodes) . .	35
Capsule and Subcapsular Sinus . . . . .	36
Cortex . . . . .	36
Paracortex . . . . .	40
Medulla . . . . .	43
Vasculature. . . . .	43
Histology of the Spleen . . . . .	45
General Microanatomy . . . . .	45
Vasculature. . . . .	45
Red Pulp . . . . .	47
White Pulp . . . . .	50
3. Technical Evaluation and Overview of Lymph Node and Spleen . . . . .	57
Indications for Lymph Node Biopsy . . . . .	57

Indications for Splenectomy . . . . .	58
Sampling and Handling the Fresh Lymph Node . . . . .	58
Sampling and Handling the Fresh Spleen . . . . .	61
Fixation and Processing . . . . .	61
Routine and Histochemical Stains . . . . .	64
Evaluation of the Lymph Node . . . . .	65
Evaluation of the Spleen . . . . .	71
4. Ancillary Studies for Evaluation of Lymph Node and Spleen . . . . .	75
Basic Concepts . . . . .	75
Immunohistochemistry Techniques . . . . .	75
Antigen Retrieval . . . . .	76
Antibodies: Clusters of Differentiation (CD) Groups . . . . .	76
Immunohistochemistry of Lymphoid Tissues . . . . .	77
B Cells . . . . .	77
T Cells . . . . .	79
Reactive Conditions Versus Malignancies . . . . .	80
Reactive Conditions Versus Lymphomas . . . . .	82
Reactive Conditions Versus B-Cell Neoplasms . . . . .	83
Reactive Conditions Versus T-Cell Neoplasms . . . . .	85
Reactive Conditions Versus Hodgkin Lymphoma . . . . .	86
Histiocytic and Myelomonocytic Antibodies . . . . .	87
Myeloid Cell Antibodies . . . . .	87
Dendritic Cell Antibodies . . . . .	88
Potential Pitfalls in Immunohistochemistry . . . . .	89
Immunohistochemistry of the Spleen . . . . .	91
Flow Cytometry . . . . .	93
Flow Cytometry of the Spleen . . . . .	93
Ultrastructural Examination of the Lymph Node and Spleen . . . . .	94
5. General Reactive Conditions in Lymph Node and Spleen . . . . .	97
Follicular Hyperplasia . . . . .	97
Interfollicular/Immunoblastic Hyperplasia . . . . .	105
Mantle Zone (Primary Follicle) Hyperplasia . . . . .	107
Marginal Zone (Monocytoid B-Cell) Hyperplasia . . . . .	109
T-Cell Hyperplasias including Nodular Paracortical T-Cell Hyperplasia and other T-Cell Nodules . . . . .	112
Mixed Pattern Hyperplasia . . . . .	116
Atypical Lymphoid Hyperplasia . . . . .	117
Sinus Histiocytosis . . . . .	119
Granulomatous Inflammation . . . . .	119

Plasmacytoid Dendritic Cells . . . . .	126
Necrotizing Lymphadenitis . . . . .	128
Progressive Transformation of Germinal Centers . . . . .	129
Regressive Changes in Germinal Centers . . . . .	133
Fatty Transformation of Lymph Nodes . . . . .	134
Hemorrhage and Infarction . . . . .	135
Perisplenitis (“Sugar-Coated” Spleen) . . . . .	137
6. Specific Clinical Entities . . . . .	143
Dermatopathic Lymphadenitis . . . . .	143
Kimura Disease . . . . .	145
Kawasaki Disease . . . . .	149
Kikuchi-Fujimoto Disease (Histiocytic Necrotizing Lymphadenitis). . . . .	150
Castleman Disease (Angiofollicular Lymph Node Hyperplasia), Hyaline-Vascular Type, Plasma Cell Type, and Multicentric Type . . . . .	155
Angioimmunoblastic Lymphadenopathy . . . . .	164
Rosai-Dorfman Disease (Sinus Histiocytosis with Massive Lymphadenopathy). . . . .	166
Hemophagocytic Syndromes . . . . .	169
Langerhans Cell Histiocytosis . . . . .	174
7. Congenital Immunodeficiency Diseases . . . . .	185
Severe Combined Immunodeficiency . . . . .	188
Autoimmune Lymphoproliferative Syndrome . . . . .	193
Common Variable Immunodeficiency. . . . .	197
Selective IgA Deficiency . . . . .	201
Hyper-IgM Syndrome. . . . .	201
Hyper-IgE Syndrome (Job Syndrome) . . . . .	204
X-Linked Agammaglobulinemia (Bruton Agammaglobulinemia) and Hypogam- maglobulinemia. . . . .	205
X-Linked Lymphoproliferative Disease (Duncan Syndrome) . . . . .	207
Griscelli Syndrome and Chediak-Higashi Syndrome. . . . .	210
Wiskott-Aldrich Syndrome. . . . .	211
Ataxia-Telangiectasia (including Nijmegen Breakage Syndrome and Berlin Breakage Syndrome) . . . . .	214
Chronic Granulomatous Disease . . . . .	216
Tuberous Sclerosis. . . . .	219
8. Bacterial Infections. . . . .	229
Gram-Positive Bacterial Infections. . . . .	229
<i>Staphylococcus</i> and <i>Streptococcus</i> . . . . .	231
<i>Corynebacterium</i> . . . . .	231
<i>Listeria Monocytogenes</i> . . . . .	233

<i>Actinomyces, Nocardia, and Rhodococcus Equi</i> . . . . .	233
<i>Tropheryma Whipplei</i> . . . . .	236
<i>Bacillus Anthracis</i> . . . . .	237
Gram-Negative Bacterial Infections . . . . .	238
<i>Bartonella Henselae</i> and <i>B Quintana</i> : Cat-Scratch Disease . . . . .	240
<i>Bartonella Henselae</i> and <i>B. Quintana</i> : Bacillary Angiomatosis . . . . .	243
<i>Salmonella Typhi</i> and <i>Salmonella Enteritidis</i> . . . . .	246
<i>Yersinia Pestis</i> : Plague . . . . .	250
Other <i>Yersinia</i> Infections . . . . .	250
<i>Francisella Tularensis</i> . . . . .	251
<i>Brucella</i> . . . . .	252
<i>Burkholderia Pseudomallei</i> . . . . .	254
<i>Mycoplasma, Treponema Pallidum, Borrelia, and Rickettsia</i> Infections . . . . .	255
<i>Coxiella Burnetii</i> . . . . .	255
<i>Chlamydia Trachomatis</i> . . . . .	257
<i>Treponema Pallidum</i> . . . . .	258
<i>Rickettsia</i> . . . . .	261
Mycobacterial Infections . . . . .	262
<i>Mycobacterium Tuberculosis</i> . . . . .	262
<i>Mycobacterium Avium-Intracellulare</i> . . . . .	266
<i>Mycobacterium Leprae</i> . . . . .	270
Bacille Calmette-Guerin. . . . .	273
Atypical Mycobacterial Infections. . . . .	274
Postsplenectomy Infections . . . . .	276
9. Viral Lymphadenopathies . . . . .	283
General Viral-Associated Lymphadenopathy. . . . .	283
Infectious Mononucleosis/Acute Epstein-Barr Virus . . . . .	283
Other Epstein-Barr Virus–Associated Lymphoid Proliferations. . . . .	291
Cytomegalovirus . . . . .	295
Herpes Simplex Virus . . . . .	298
Varicella-Zoster Virus . . . . .	301
Human Herpesvirus-8. . . . .	303
Human Herpesvirus-6. . . . .	305
Measles Virus . . . . .	308
Rubella Virus. . . . .	309
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome . . . . .	309
Zoonotic Viruses. . . . .	316
Parvovirus B19 . . . . .	317
Smallpox ( <i>Variola Virus</i> ), Cowpox, Monkeypox . . . . .	318

	Severe Acute Respiratory Syndrome . . . . .	318
	Poliovirus . . . . .	319
	Postvaccinial Lymphadenitis . . . . .	320
10.	Fungal Infections . . . . .	327
	<i>Cryptococcus Neoformans</i> . . . . .	328
	<i>Histoplasma Capsulatum</i> . . . . .	328
	<i>Blastomyces Dermatitidis</i> . . . . .	332
	<i>Coccidioides Immitis</i> . . . . .	333
	<i>Paracoccidioides Brasiliensis</i> . . . . .	337
	<i>Pneumocystis Jiroveci</i> . . . . .	338
	<i>Penicillium Marneffeii</i> . . . . .	340
	<i>Candida, Torulopsis Glabrata, and Dermatophytes</i> . . . . .	341
	<i>Aspergillus</i> . . . . .	342
	Zygomycetes (including <i>Mucor</i> and <i>Rhizopus</i> ) . . . . .	344
	Chromoblastomycosis . . . . .	344
	<i>Pseudoallierichia</i> and <i>Petriellidium</i> . . . . .	345
	<i>Sporothrix Schenckii</i> . . . . .	345
11.	Parasitic and Miscellaneous Infections . . . . .	347
	<i>Toxoplasma Gondii</i> . . . . .	347
	<i>Entamoeba Histolytica</i> . . . . .	349
	Other Protozoa ( <i>Microsporidium, Cryptosporidium, and Isospora Belli</i> ) . . . . .	351
	Filaria . . . . .	351
	Nematode Infections (including <i>Strongyloides</i> ) and Other Parasitic Worms . . . . .	356
	<i>Echinococcus</i> . . . . .	358
	<i>Leishmania Donovanii</i> . . . . .	360
	<i>Trypanosoma Cruzi</i> and <i>T. Brucei</i> . . . . .	362
	<i>Schistosoma</i> . . . . .	363
	<i>Plasmodium</i> . . . . .	364
	<i>Babesia</i> . . . . .	368
	<i>Rhinosporidium Seeberi</i> . . . . .	369
	<i>Prototheca</i> . . . . .	369
	Prions . . . . .	370
12.	Systemic and Autoimmune Abnormalities . . . . .	375
	Immune Thrombocytopenic Purpura . . . . .	375
	Autoimmune Hemolytic Anemia . . . . .	380
	Sarcoidosis . . . . .	381
	Systemic Lupus Erythematosus . . . . .	383
	Rheumatoid Arthritis and Adult-Onset Juvenile Rheumatoid Arthritis (Still Disease) . . . . .	388
	Felty Syndrome . . . . .	390

Large Granular Lymphocytosis . . . . .	391
Behcet Disease . . . . .	394
Thrombotic Thrombocytopenic Purpura. . . . .	394
Vasculitides (Wegener Granulomatosis, Polyarteritis Nodosa, Churg-Strauss Disease, Henoch-Schonlein Purpura) . . . . .	396
13. Hematologic Disorders . . . . .	405
Hereditary Spherocytosis/Elliptocytosis. . . . .	405
Sickle Cell Disease . . . . .	406
Hemoglobinopathies Associated with Unstable Hemoglobins . . . . .	410
Thalassemia Syndromes . . . . .	410
Erythrocyte Enzyme Deficiencies. . . . .	411
Pyruvate Kinase Deficiency . . . . .	411
Extramedullary Hematopoiesis . . . . .	412
14. Medication and Treatment Effects . . . . .	419
Rituximab Therapy and Other Monoclonal Antibody Therapies for Lymphoma . . .	419
Corticosteroid Therapy. . . . .	421
Methotrexate . . . . .	422
Anticonvulsant Medications . . . . .	424
Granulocyte-Colony Stimulating Factor and Other Cytokines. . . . .	427
Ionizing Radiation Effects . . . . .	430
Sulfasalazine . . . . .	433
Clofazimine Crystal Deposition. . . . .	434
Bone Marrow Transplantation and Graft-Versus-Host Disease . . . . .	434
Gold Therapy (Chrysotherapy) . . . . .	435
15. Foreign Bodies and Chemicals . . . . .	439
Proteinaceous Lymphadenopathy . . . . .	439
Extracellular Immunoglobulin Deposits . . . . .	440
Amyloid Deposits/Amyloidosis . . . . .	445
Tamm-Horsfall Protein Deposits . . . . .	449
Lipid Deposits. . . . .	450
Lymphangiogram Effect. . . . .	450
Silicone Deposits . . . . .	454
Histiocytic Lymphadenopathy after Joint Prosthesis . . . . .	456
Berylliosis . . . . .	458
Asbestos Deposits . . . . .	459
Silicosis . . . . .	460
Hemochromatosis . . . . .	462
Thorotrast Deposition . . . . .	463
Talc Deposition. . . . .	464

	Synthetic Polymer Deposition . . . . .	466
	Tattoo Pigment/Anthracosis/Lipofuscin Deposition . . . . .	466
16.	Metabolic Diseases . . . . .	477
	Overview. . . . .	477
	Gaucher Disease . . . . .	481
	Niemann-Pick Disease . . . . .	484
	Sea-Blue (Ceroid) Histiocytosis. . . . .	486
17.	Physical Injury and Vascular Abnormalities . . . . .	491
	Splenic Rupture (Traumatic and Atraumatic) . . . . .	491
	Fibrocongestive Splenomegaly (including Portal Hypertension) . . . . .	494
	Infarction of Lymph Node and Spleen . . . . .	497
	Changes Associated with Fine Needle Aspiration/Biopsy . . . . .	501
	Vascular Transformation of Lymph Node Sinuses (Nodal Angiomatosis). . . . .	502
	Lymphangiectasia and Peliosis. . . . .	505
	Lymphangioma and Lymphangiomatosis . . . . .	507
	Other Vascular Tumors. . . . .	508
	Splenic Artery Aneurysms . . . . .	516
18.	Benign Disorders of Unclear Etiology and Neoplasms . . . . .	523
	Splenic Hamartoma . . . . .	523
	Inflammatory Pseudotumor (Lymph Node and Spleen) . . . . .	528
	Palisaded Myofibroblastoma . . . . .	537
	Lipomatosis, Lipoma, and Fatty Replacement of Lymph Node . . . . .	539
	Angiomyolipoma . . . . .	541
	Angiomyomatous Hamartoma, Lymphangiomyoma, Leiomyomatosis, and Leiomyoma . . . . .	542
	Metastatic Tumors of Spleen . . . . .	547
19.	Splenic Cysts. . . . .	553
	Nonparasitic Cysts . . . . .	553
	Pseudocysts . . . . .	553
	True Cysts: Splenic Mesothelial, Epidermoid, and Epithelial . . . . .	554
	True Cysts: Splenic Dermoid . . . . .	557
	Parasitic Cysts. . . . .	557
	Index . . . . .	561